新华医疗(600587) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥2,215,207,489.58, representing a year-on-year increase of 16.93%[5] - The net profit attributable to shareholders for Q3 2022 was ¥97,628,939.92, a decrease of 10.12% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 119.12% year-on-year, amounting to ¥81,587,322.38[5] - The basic earnings per share for Q3 2022 was ¥0.24, down 11.11% from the previous year[7] - Total operating revenue for the first three quarters of 2022 was CNY 6,650,498,257.60, a decrease of 9.5% compared to CNY 7,354,887,333.68 in the same period of 2021[20] - Net profit for the third quarter of 2022 was CNY 429,845,915.47, slightly down from CNY 432,378,017.13 in the same quarter of 2021[22] - Total comprehensive income attributable to the parent company was CNY 428,801,536.13, a decrease of 1.23% compared to CNY 436,876,317.36 in the same period last year[23] - Basic and diluted earnings per share were both CNY 1.03, down from CNY 1.08 year-over-year[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,554,977,602.86, an increase of 8.10% compared to the end of the previous year[7] - The total current assets increased to approximately RMB 7.11 billion, compared to RMB 6.18 billion at the end of 2021, reflecting an increase of about 15.1%[18] - The total assets as of the end of the third quarter of 2022 reached CNY 12,554,977,602.86, up from CNY 11,613,893,656.00 at the end of the previous year[20] - The total liabilities increased to CNY 6,908,767,265.50 from CNY 6,345,464,086.08, indicating a rise of 8.8%[20] - The equity attributable to shareholders of the parent company rose to CNY 5,288,886,131.41, compared to CNY 4,914,714,269.04 in the previous year[20] Cash Flow - The company reported a net cash flow from operating activities of -¥53,736,820.97 for the year-to-date, a decline of 104.18% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of CNY -53,736,820.97, compared to a net inflow of CNY 1,285,964,030.07 in the previous year[27] - Cash inflow from operating activities totaled CNY 7,545,821,521.40, down 16.1% from CNY 8,997,520,588.51 in the same period last year[27] - Cash outflow from operating activities was CNY 7,599,558,342.37, a decrease of 1.45% compared to CNY 7,711,556,558.44 in the previous year[27] - Cash flow from investing activities resulted in a net outflow of CNY -171,173,494.37, compared to a net outflow of CNY -18,013,508.09 in the previous year[27] - Cash flow from financing activities generated a net inflow of CNY 88,920,486.54, contrasting with a net outflow of CNY -1,083,317,643.61 in the same period last year[27] - The total cash and cash equivalents at the end of the period were CNY 1,187,348,298.60, down from CNY 1,348,131,563.67 at the end of the same period last year[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 28,914[12] - The largest shareholder, Shandong Yiyang Health Industry Development Group Co., Ltd., holds 116,947,642 shares, accounting for 28.39% of total shares[12] Operational Challenges - The company experienced a decrease in net profit due to changes in revenue structure at its subsidiary, Shanghai Taimei Medical Equipment Co., Ltd.[9] - The company reported a decrease in revenue primarily due to the termination of a business agency with Johnson & Johnson Medical Devices in June 2021, affecting the revenue structure of its subsidiary, Shanghai Taimei Medical Equipment Co., Ltd.[14] - The company is focused on optimizing its product structure, leading to steady growth in revenue from medical devices and pharmaceutical equipment[9] - The company has ongoing litigation related to the acquisition of shares, which may impact future financial performance[14] - The company is currently appealing a court ruling regarding the acquisition of a 10% stake in Shanghai Yuanyue Pharmaceutical Machinery Co., Ltd., which was valued at RMB 23.94 million[14] Inventory and Expenses - Inventory as of September 30, 2022, was approximately RMB 3.27 billion, up from RMB 2.31 billion at the end of 2021, indicating an increase of about 42%[18] - Research and development expenses for the third quarter of 2022 amounted to CNY 242,536,876.62, an increase of 35% compared to CNY 179,676,926.65 in the previous year[22]